Adaptimmune Therapeutics (ADAP) Short Interest Ratio & Short Volume → Executive Order To Wipe Out Your Bank Accounts (From Oasis Gold) (Ad) Free ADAP Stock Alerts $1.02 -0.01 (-0.97%) (As of 06/7/2024 08:51 PM ET) Add Compare Share Share Short InterestStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Adaptimmune Therapeutics Short Interest DataCurrent Short Interest3,440,000 sharesPrevious Short Interest3,520,000 sharesChange Vs. Previous Month-2.27%Dollar Volume Sold Short$4.27 millionShort Interest Ratio2.5 Days to CoverLast Record DateMay 15, 2024Outstanding Shares246,820,000 sharesPercentage of Shares Shorted1.39%Today's Trading Volume1,076,500 sharesAverage Trading Volume1,734,722 sharesToday's Volume Vs. Average62% Short Selling Adaptimmune Therapeutics ? Sign up to receive the latest short interest report for Adaptimmune Therapeutics and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartADAP Short Interest Over TimeADAP Days to Cover Over TimeADAP Percentage of Float Shorted Over Time Ad Oasis GoldExecutive Order To Wipe Out Your Bank AccountsDon't wait until it's too late. The digital dollar is nearing the end of its trial period, and the window of opportunity to protect your interests is closing fast.Click Here To Get Your FREE Guide Now! Adaptimmune Therapeutics Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 5/15/20243,440,000 shares $4.27 million -2.3%N/A2.5 $1.24 4/30/20243,520,000 shares $4.19 million +3.2%N/A2.3 $1.19 4/15/20243,410,000 shares $3.58 million +6.6%N/A1.7 $1.05 3/31/20243,200,000 shares $5.06 million +2.9%N/A1.7 $1.58 3/15/20243,110,000 shares $4.60 million +11.1%N/A1.7 $1.48 2/29/20242,800,000 shares $4.40 million -4.4%N/A1.6 $1.57 Get the Latest News and Ratings for ADAP and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Adaptimmune Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 2/15/20242,930,000 shares $3.66 million -37.8%N/A2.1 $1.25 1/31/20244,710,000 shares $4.52 million -18.4%N/A3.8 $0.96 1/15/20245,770,000 shares $4.75 million +1.2%N/A9.3 $0.82 12/31/20235,700,000 shares $4.52 million -6.9%N/A9.6 $0.79 12/15/20236,120,000 shares $2.75 million -0.8%N/A12 $0.45 11/30/20236,170,000 shares $3.09 million +3.0%N/A14.4 $0.50 11/15/20235,990,000 shares $3.00 million +2.4%N/A14.3 $0.50 10/31/20235,850,000 shares $3.16 million -12.6%N/A14.2 $0.54 10/15/20236,690,000 shares $4.39 million +12.1%N/A14.7 $0.66 9/30/20235,970,000 shares $4.66 million -1.3%N/A12.2 $0.78 9/15/20236,050,000 shares $4.91 million +3.1%N/A10.3 $0.81 8/31/20235,870,000 shares $4.58 million +1.9%N/A8.3 $0.78 8/15/20235,760,000 shares $4.49 million +0.4%N/A6.5 $0.78 7/31/20235,740,000 shares $5.41 million +1.4%3.9%6.5 $0.94 7/15/20235,660,000 shares $5.10 million -5.5%3.8%6.2 $0.90 6/30/20235,990,000 shares $5.54 million -19.6%4.1%6.3 $0.93 6/15/20237,450,000 shares $7.52 million -25.2%5.1%8.4 $1.01 5/31/20239,960,000 shares $10.16 million +8.7%6.8%11.6 $1.02 5/15/20239,160,000 shares $12.73 million +2.0%6.2%12.1 $1.39 4/30/20238,980,000 shares $12.75 million +19.9%6.2%12.5 $1.42 4/15/20237,490,000 shares $10.19 million +11.3%5.1%11.6 $1.36 3/31/20236,730,000 shares $7.34 million +28.7%4.6%11.9 $1.09 3/15/20235,230,000 shares $5.91 million +81.0%3.6%9.6 $1.13 2/28/20232,890,000 shares $5.12 million +1.8%2.0%6.5 $1.77 2/15/20232,840,000 shares $4.69 million +1.4%2.0%8.4 $1.65 1/31/20232,800,000 shares $5.24 million +3.3%1.9%6.4 $1.87 1/15/20232,710,000 shares $5.07 million -8.1%1.9%5.1 $1.87 12/30/20222,950,000 shares $4.31 million +7.7%2.0%5.6 $1.46 12/15/20222,740,000 shares $3.73 million -1.4%1.9%5.3 $1.36 11/30/20222,780,000 shares $6.03 million -26.1%1.9%5.3 $2.17 11/15/20223,760,000 shares $8.95 million +12.6%2.6%7.6 $2.38 10/31/20223,340,000 shares $4.74 million -10.0%2.3%7.9 $1.42 10/15/20223,710,000 shares $4.19 million -6.6%2.6%9.3 $1.13 9/30/20223,970,000 shares $4.27 million +7.0%2.8%13.5 $1.08Executive Order To Wipe Out Your Bank Accounts (Ad)Don't wait until it's too late. The digital dollar is nearing the end of its trial period, and the window of opportunity to protect your interests is closing fast.Click Here To Get Your FREE Guide Now! 9/15/20223,710,000 shares $6.01 million +0.3%2.6%12.3 $1.62 8/31/20223,700,000 shares $7.33 million +1.7%2.6%11.6 $1.98 8/15/20223,640,000 shares $8.77 million -2.2%2.5%10.6 $2.41 7/31/20223,720,000 shares $6.88 million -7.9%2.6%9.7 $1.85 7/15/20224,040,000 shares $6.91 million +3.3%2.8%8.4 $1.71 6/30/20223,910,000 shares $6.65 million -4.6%2.7%6.9 $1.70 6/15/20224,100,000 shares $6.60 million -4.7%2.9%7.2 $1.61 5/31/20224,300,000 shares $6.19 million +0.5%3.1%6 $1.44 5/15/20224,280,000 shares $6.03 million -5.5%3.1%4.4 $1.41 4/30/20224,530,000 shares $7.79 million -2.2%3.3%4.5 $1.72 4/15/20224,630,000 shares $8.84 million -0.4%3.4%4.9 $1.91 3/31/20224,650,000 shares $9.58 million -10.2%3.4%4.8 $2.06 3/15/20225,180,000 shares $8.96 million -3.2%3.8%5.1 $1.73 2/28/20225,350,000 shares $13.91 million -2.4%3.9%5.4 $2.60 2/15/20225,480,000 shares $17.37 million +3.0%4.0%7.1 $3.17 1/31/20225,320,000 shares $15.53 million +4.1%3.9%6 $2.92 1/15/20225,110,000 shares $16.86 million +5.6%3.7%5.9 $3.30 12/31/20214,840,000 shares $18.15 million +29.4%3.5%5.8 $3.75 12/15/20213,740,000 shares $13.76 million +10.7%2.7%4.4 $3.68 11/30/20213,380,000 shares $14.03 million +8.3%2.5%3 $4.15 11/15/20213,120,000 shares $13.57 million +5.8%2.3%1.6 $4.35 10/29/20212,950,000 shares $14.96 million -3.9%2.2%1.5 $5.07 10/15/20213,070,000 shares $16.36 million -8.4%2.2%1.6 $5.33 9/30/20213,350,000 shares $17.32 million -44.9%2.4%1.8 $5.17 9/15/20216,080,000 shares $32.83 million +47.9%4.4%3.3 $5.40 8/31/20214,110,000 shares $21.25 million +41.2%3.0%2.5 $5.17 8/13/20212,910,000 shares $11.61 million +8.2%2.1%4 $3.99 7/30/20212,690,000 shares $9.60 million -5.6%2.0%3.3 $3.57 7/15/20212,850,000 shares $10.66 million -5.0%2.1%3.3 $3.74 6/30/20213,000,000 shares $12.78 million -21.7%2.2%3.5 $4.26 6/15/20213,830,000 shares $15.86 million -2.5%2.8%4.2 $4.14 5/28/20213,930,000 shares $19.77 million -1.8%2.9%4.7 $5.03 5/14/20214,000,000 shares $18.24 million -0.7%N/A4.8 $4.56 4/30/20214,030,000 shares $23.29 million +5.0%N/A4.6 $5.78 4/15/20213,840,000 shares $19.35 million +27.2%N/A4.4 $5.04 3/31/20213,020,000 shares $15.25 million +64.1%N/A3.1 $5.05 3/15/20211,840,000 shares $10.08 million -0.5%N/A1.5 $5.48 2/26/20211,850,000 shares $10.99 million +22.5%N/A1.3 $5.94 2/12/20211,510,000 shares $10.01 million +4.9%N/A1 $6.63 1/29/20211,440,000 shares $7.89 million +8.3%N/A0.9 $5.48 1/15/20211,330,000 shares $8.11 million -64.1%N/A0.8 $6.10 12/31/20203,700,000 shares $20.02 million +31.2%N/A2 $5.41 12/15/20202,820,000 shares $11.56 million No ChangeN/A1.7 $4.10 11/30/20202,820,000 shares $13.85 million -5.1%N/A2.1 $4.91 11/15/20202,970,000 shares $14.82 million -35.0%N/A2.5 $4.99 10/30/20204,570,000 shares $20.70 million -29.0%N/A4.1 $4.53 10/15/20206,440,000 shares $51.20 million +21.1%N/A7 $7.95 9/30/20205,320,000 shares $42.45 million +8.6%N/A7.5 $7.98 9/15/20204,900,000 shares $49.39 million +50.8%N/A6.3 $10.08 8/31/20203,250,000 shares $28.28 million -18.8%N/A4.1 $8.70Executive Order To Wipe Out Your Bank Accounts (Ad)Don't wait until it's too late. The digital dollar is nearing the end of its trial period, and the window of opportunity to protect your interests is closing fast.Click Here To Get Your FREE Guide Now! 8/14/20204,000,000 shares $32.04 million +2.8%N/A1.3 $8.01 7/31/20203,890,000 shares $36.37 million +3.5%N/A1.2 $9.35 7/15/20203,760,000 shares $31.96 million +1.1%N/A1.2 $8.50 6/30/20203,720,000 shares $34.56 million -5.6%N/A1.2 $9.29 6/15/20203,940,000 shares $41.09 million +605.1%N/A1.3 $10.43 5/29/2020558,800 shares $6.19 million +39.4%N/A0.2 $11.07 5/15/2020401,000 shares $1.74 million -45.2%N/A0.7 $4.35 4/30/2020731,400 shares $2.46 million -10.0%N/A1.6 $3.36 4/15/2020812,400 shares $2.68 million +14.7%0.9%1.6 $3.30 3/31/2020708,600 shares $2.44 million +70.5%0.8%0.4 $3.45 3/13/2020415,600 shares $1.25 million -11.4%0.5%1.1 $3.01 2/28/2020468,800 shares $1.32 million -28.2%0.5%0.2 $2.81 2/14/2020653,000 shares $2.00 million +11.8%0.7%0.3 $3.06 1/31/2020584,100 shares $2.05 million -66.4%0.7%0.3 $3.51 1/15/20201,740,000 shares $7.24 million +13.7%2.0%0.9 $4.16 12/31/20191,530,000 shares $6.00 million -35.2%1.7%1 $3.92 8/15/20193,798,400 shares $5.43 million +4.7%4.4%13 $1.43 ADAP Short Interest - Frequently Asked Questions What is Adaptimmune Therapeutics' current short interest? Short interest is the volume of Adaptimmune Therapeutics shares that have been sold short but have not yet been closed out or covered. As of May 15th, traders have sold 3,440,000 shares of ADAP short. Learn More on Adaptimmune Therapeutics' current short interest. What is a good short interest ratio for Adaptimmune Therapeutics? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. ADAP shares currently have a short interest ratio of 2.0. Learn More on Adaptimmune Therapeutics's short interest ratio. Which institutional investors are shorting Adaptimmune Therapeutics? As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Adaptimmune Therapeutics: Concourse Financial Group Securities Inc.. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission. Is Adaptimmune Therapeutics' short interest increasing or decreasing? Adaptimmune Therapeutics saw a decrease in short interest in the month of May. As of May 15th, there was short interest totaling 3,440,000 shares, a decrease of 2.3% from the previous total of 3,520,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. How does Adaptimmune Therapeutics' short interest compare to its competitors? Here is how the short interest of companies in the sector of "medical" compare to Adaptimmune Therapeutics: Cellectis S.A. (0.92%), bluebird bio, Inc. (28.90%), Precigen, Inc. (10.65%), Atara Biotherapeutics, Inc. (9.65%), Relay Therapeutics, Inc. (8.96%), Inhibrx, Inc. (3.91%), Mesoblast Limited (0.68%), Humacyte, Inc. (4.64%), Scholar Rock Holding Co. (16.71%), CARGO Therapeutics, Inc. (13.82%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: T-Mobile US, Inc. ($3.81 billion), Charter Communications, Inc. ($3.30 billion), Occidental Petroleum Co. ($3.10 billion), General Motors ($2.84 billion), Moderna, Inc. ($2.77 billion), AppLovin Co. ($2.22 billion), Royal Caribbean Cruises Ltd. ($2.22 billion), Coinbase Global, Inc. ($2.16 billion), Tractor Supply ($2.12 billion), and Williams-Sonoma, Inc. ($2.12 billion). View all of the most shorted stocks. What does it mean to sell short Adaptimmune Therapeutics stock? Short selling ADAP is an investing strategy that aims to generate trading profit from Adaptimmune Therapeutics as its price is falling. ADAP shares are trading down $0.01 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Adaptimmune Therapeutics? A short squeeze for Adaptimmune Therapeutics occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of ADAP, which in turn drives the price of the stock up even further. How often is Adaptimmune Therapeutics' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including ADAP, twice per month. The most recent reporting period available is May, 15 2024. More Short Interest Resources from MarketBeat Related Companies: CLLS Short Interest Data BLUE Short Interest Data PGEN Short Interest Data ATRA Short Interest Data RLAY Short Interest Data INBX Short Interest Data MESO Short Interest Data HUMA Short Interest Data SRRK Short Interest Data CRGX Short Interest Data Short Interest Tools: Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:ADAP) was last updated on 6/10/2024 by MarketBeat.com Staff From Our PartnersWrite this ticker symbol down…A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredAlert: Your Bank is Dying – Act Now or Lose Everything!Get your free information kit NOW, before it’s too late. Inside you’ll get the 3 secret strategies you can put...Priority Gold | SponsoredIt's time to ween off Chinese lithium!As the lithium rush continues, this small-cap NASDAQ-traded company may be one of the brightest and most promi...Smallcaps Daily | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredNo Strings Attached: Get 30 Days of Hedgeye’s Top Stock Picks for FreeOptimize your stock investing strategy with Hedgeye's Investing Ideas, where rigorous fundamental stock analys...Hedgeye | SponsoredHurry! Buy this stock before the Robinhood traders do!Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredAI's Next Magnificent SevenThe Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Adaptimmune Therapeutics plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Adaptimmune Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.